Table 6 Symptoms and symptom burden 5 years post-baseline.

From: Five-year follow-up of the OptiTrain trial on concurrent resistance and high-intensity interval training during chemotherapy for patients with breast cancer

Memorial symptom

assessment scale

(MSAS)

 

Baseline

Mean ± SD

16 weeks

Mean ± SD

2 years

Mean ± SD

5 years

Mean ± SD

 

Baseline to 5 years

Between-group differences

Mean difference (95% CI)

ES

Total Symptoms

RT-HIIT

0.74 ± 0.53

0.74 ± 0.50

0.51 ± 0.39

0.45 ± 0.41

RT-HIIT versus UC

− 0.05 (− 0.22, 0.12)

− 0.04

AT-HIIT

0.65 ± 0.41

0.76 ± 0.51

0.39 ± 0.31

0.41 ± 0.32

AT-HIIT versus UC

− 0.10 (− 0.27, 0.07)

0.07

UC

0.59 ± 0.50

0.85 ± 0.60

0.40 ± 0.33

0.32 ± 0.36

   

Symptom burden

RT-HIIT

0.91 ± 0.72

0.77 ± 0.62

0.62 ± 0.57

0.59 ± 0.66

RT-HIIT versus UC

0.05 (− 0.20, 0.31)

0.06

AT-HIIT

0.75 ± 0.58

0.66 ± 0.59

0.44 ± 0.50

0.45 ± 0.44

AT-HIIT versus UC

− 0.12 (− 0.37, 0.14)

0.09

UC

0.71 ± 0.71

0.89 ± 0.67

0.52 ± 0.53

0.35 ± 0.51

   

Physical symptoms

RT-HIIT

0.74 ± 0.59

0.68 ± 0.57

0.35 ± 0.37

0.31 ± 0.38

RT-HIIT versus UC

− 0.08 (− 0.25, 0.10)

− 0.24

AT-HIIT

0.67 ± 0.49

0.75 ± 0.59

0.32 ± 0.33

0.30 ± 0.30

AT-HIIT versus UC

− 0.12 (− 0.30, 0.06)

− 0.15

UC

0.52 ± 0.56

0.77 ± 0.62

0.30 ± 0.35

0.23 ± 0.34

   

Psychological symptoms

RT-HIIT

0.97 ± 0.76

1.02 ± 0.77

0.83 ± 0.74

0.88 ± 0.93

RT-HIIT versus UC

0.22 (− 0.13, 0.57)

0.39

AT-HIIT

0.81 ± 0.64

0.88 ± 0.73

0.58 ± 0.56

0.63 ± 0.62

AT-HIIT versus UC

− 0.03 (− 0.38, 0.32)

0.30

UC

0.81 ± 0.77

1.11 ± 0.83

0.58 ± 0.60

0.42 ± 0.54

   
  1. SD standard deviation, CI confidence interval, ES effect size, RT-HIIT resistance training and high-intensity interval exercise group, AT-HIIT moderate-intensity and high-intensity interval training group,
  2. UC usual care, ES effect size.
  3. *p < 0.05.
Back to article page